LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (ACT) (OTCBB: ACTC) announced today that it has signed a clinical trial agreement with Chandler Regional Medical Center and Mercy Gilbert Medical Center, members of Catholic Healthcare West (CHW), the nation’s eighth largest healthcare system, to become ACT’s first clinical trial sites for the Phase II myoblast study. In addition, CHW has received Institutional Review Board approval for the clinical trial, which is expected to begin soon. ACT’s myoblast program is an autologous adult stem cell therapy for the treatment of heart disease that has successfully completed four Phase I clinical trials and received clearance from the Food and Drug Administration to begin Phase II trials.
